Eckert & Ziegler SE (ETR:EUZ)
59.40
+0.60 (1.02%)
Apr 28, 2025, 9:47 AM CET
Eckert & Ziegler SE Revenue
In the year 2024, Eckert & Ziegler SE had annual revenue of 295.85M EUR with 20.22% growth. Eckert & Ziegler SE had revenue of 80.36M in the quarter ending December 31, 2024, with 29.13% growth.
Revenue
295.85M
Revenue Growth
+20.22%
P/S Ratio
4.14
Revenue / Employee
272.67K
Employees
1,085
Market Cap
1.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 295.85M | 49.76M | 20.22% |
Dec 31, 2023 | 246.09M | 23.86M | 10.74% |
Dec 31, 2022 | 222.23M | 41.79M | 23.16% |
Dec 31, 2021 | 180.44M | 4.30M | 2.44% |
Dec 31, 2020 | 176.14M | -2.35M | -1.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius SE & Co. KGaA | 21.83B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Eckert & Ziegler SE News
- 3 days ago - EQS-News: Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE - Wallstreet:Online
- 3 days ago - EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm - Wallstreet:Online
- 16 days ago - EQS-DD: Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 18,048 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an ... - Wallstreet:Online
- 17 days ago - EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024 - Wallstreet:Online
- 17 days ago - EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig - Wallstreet:Online
- 4 weeks ago - EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs - Wallstreet:Online
- 4 weeks ago - EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities - Wallstreet:Online
- 5 weeks ago - EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply - Wallstreet:Online